Rezetapopt Shows 44% Response Rate in Ovarian Cancer

Rezetapopt demonstrated a 44.4% overall response rate and durable responses lasting over eight months in patients with ovarian cancer harboring a p53 Y220C mutation, according to interim phase 2 data.

Dr. Alison Schram of Memorial Sloan Kettering Cancer Center presented findings from the PINNACLE phase 2 clinical trial evaluating rezetapopt, an oral therapy designed to target the p53 Y220C mutation, in patients with ovarian cancer.

Among patients with this specific mutation, treatment was generally well tolerated, with mostly low-grade side effects such as nausea. The therapy also showed encouraging efficacy, with 44.4% of patients experiencing significant and durable tumor shrinkage.

The duration of response exceeded eight months on average, indicating that patients were able to remain on therapy for extended periods while maintaining both tolerability and clinical benefit.

Transcript

What interim results from the PINNACLE phase 2 trial of rezetapopt have you seen in patients with ovarian cancer harboring a p53 Y220C mutation, particularly in terms of safety and effectiveness?

I presented the PYNNACLE phase 2 clinical trial of rezetapopt, which is an oral drug that targets p53 Y220C, which is a specific p53 mutation. Today I presented the interim results from the ovarian cancer cohort in that trial.

In patients with ovarian cancer who have a p53 Y220C mutation, which is a very specific mutation in p53, rezetapopt treatment was well tolerated, with mostly low-grade side effects like nausea, and was generally very well tolerated. We also looked at the effectiveness of the treatment, and the overall response rate was 44.4%, meaning 44% of patients had significant and durable tumor shrinkage. The duration of response was over eight months on average. Patients generally had durable responses and were able to remain on therapy for many months with good tolerability and efficacy.

Transcript has been edited for clarity and conciseness.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.